Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC Jr, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J. Gathe JC Jr, et al. Among authors: wood r. Clin Ther. 2006 May;28(5):745-54. doi: 10.1016/j.clinthera.2006.05.011. Clin Ther. 2006. PMID: 16861096 Clinical Trial.
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.
Wood R, Eron J, Arasteh K, Teofilo E, Trepo C, Livrozet JM, Yeo J, Millard J, Wire MB, Naderer OJ. Wood R, et al. Clin Infect Dis. 2004 Aug 15;39(4):591-4. doi: 10.1086/422452. Epub 2004 Jul 26. Clin Infect Dis. 2004. PMID: 15356829 Clinical Trial.
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ. Wood R, et al. Antimicrob Agents Chemother. 2004 Jan;48(1):116-23. doi: 10.1128/AAC.48.1.116-123.2004. Antimicrob Agents Chemother. 2004. PMID: 14693528 Free PMC article. Clinical Trial.
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.
Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, Wood R, Holmes CB, Pillay S, Conradie F, McIntyre J, Losina E, Walensky RP; CEPAC-International and OCTANE Investigators. Ciaranello AL, et al. Among authors: wood r. AIDS. 2011 Feb 20;25(4):479-92. doi: 10.1097/QAD.0b013e3283428cbe. AIDS. 2011. PMID: 21293199 Free PMC article.
Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007.
Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, Giddy J, Wood R, Prozesky H, Mohapi L, Graber C, Egger M, Boulle A, Myer L; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration. Cornell M, et al. Among authors: wood r. AIDS. 2010 Sep 10;24(14):2263-70. doi: 10.1097/QAD.0b013e32833d45c5. AIDS. 2010. PMID: 20683318 Free PMC article.
4,487 results